Medpace(US:MEDP)2025-04-22 20:02Revenue and Income - Revenue for the three months ended March 31, 2025, was $558.6 million, an increase of 9.3% compared to $511.0 million for the same period in 2024[86]. - Total revenue increased by $47.5 million, reaching $558.6 million for the three months ended March 31, 2025, compared to $511.0 million for the same period in 2024, driven by growth in Metabolic, Oncology, and Central Nervous System therapeutic areas[87]. - Income from operations for the three months ended March 31, 2025, was $113.5 million, compared to $104.1 million in 2024[86]. - Net income for the period was $114.6 million, an increase of 11.7% from $102.6 million in 2024[86]. - Net income increased by $12.0 million to $114.6 million for the three months ended March 31, 2025, compared to $102.6 million for the same period in 2024[86]. Costs and Expenses - Total direct costs for the same period were $380.2 million, up 6.8% from $355.9 million in 2024[86]. - Total direct costs rose by $24.3 million to $380.2 million for the three months ended March 31, 2025, primarily due to higher reimbursed out-of-pocket expenses and personnel costs[88]. - Selling, general and administrative expenses increased by 31.3% to $57.9 million from $44.1 million in 2024[86]. - Selling, general and administrative expenses increased by $13.8 million to $57.9 million for the three months ended March 31, 2025, mainly due to higher personnel costs[89]. Business Awards and Backlog - Net new business awards were $500.0 million for the three months ended March 31, 2025, compared to $615.6 million for the same period in 2024[81]. - Backlog as of March 31, 2025, decreased by $61.1 million, or 2.1%, to $2,846.0 million from $2,907.1 million in 2024[82]. - Backlog decreased by $61.1 million, or 2.1%, to $2,846.0 million as of March 31, 2025, compared to $2,907.1 million as of March 31, 2024[82]. Cash Flow and Financing - Net cash provided by operating activities was $125.8 million for the three months ended March 31, 2025, beginning with net income of $114.6 million[98]. - Net cash used in investing activities was $10.0 million for the three months ended March 31, 2025, primarily for property and equipment expenditures[100]. - Net cash used in financing activities was $346.0 million for the three months ended March 31, 2025, mainly related to $371.9 million in stock repurchases[101]. - The company repurchased 1,193,011 shares for $389.8 million during the three months ended March 31, 2025, with a total repurchase authorization now at $1.1 billion[102]. - Net cash used in financing activities was $346.0 million for the three months ended March 31, 2025, primarily due to $371.9 million in stock repurchases[101]. - The company expects to fund its operational growth through cash flow from operations and borrowings under existing or future credit facilities[95]. Tax and Capital Expenditures - The overall effective tax rate decreased to 3.0% for the three months ended March 31, 2025, from 9.0% for the same period in 2024[93]. - The effective tax rate decreased to 3.0% for the three months ended March 31, 2025, down from 9.0% for the same period in 2024, due to increased excess tax benefits from share-based compensation[93]. - Capital spending as a percentage of revenue increased by 71 basis points to 1.79% for the three months ended March 31, 2025, compared to the same period in the prior year[95]. Employment and Company Structure - The company employed approximately 5,900 employees across 44 countries as of March 31, 2025[68]. Cash and Credit Facilities - As of March 31, 2025, cash and cash equivalents were $441.4 million, down from $669.4 million as of December 31, 2024[94]. - The company has a $10.0 million revolving line of credit under its unsecured credit facility, which was amended since its inception on September 30, 2019[94]. - As of March 31, 2025, the company had $10.0 million available for borrowing under the Credit Facility, with an increased borrowing limit of up to $600.0 million following Amendment No. 8 to the Loan Agreement[95]. Changes in Operating Assets and Liabilities - Changes in operating assets and liabilities used $18.9 million in operating cash flows, driven by decreased accrued expenses of $23.2 million[98]. Stock Repurchase Program - The Board approved an increase of $1.0 billion to the company's stock repurchase program on April 17, 2025[103].